临床数据-话题@MedSci

#临床数据#

91篇内容 | 2710人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2016735, encodeId=2ee42016e3541, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=屡败屡战的千亿级阿尔茨海默病的药企和临床数据解读, objectType=article, longId=177002, objectId=4e311e70024c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e311e70024c, replyNumber=0, likeNumber=106, createdTime=2020-01-23, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e311e70024c, moduleTitle=屡败屡战的千亿级阿尔茨海默病的药企和临床数据解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e311e70024c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016733, encodeId=41162016e33c2, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, objectType=article, longId=168735, objectId=7d54168e353a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d54168e353a, replyNumber=0, likeNumber=82, createdTime=2020-03-29, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d54168e353a, moduleTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d54168e353a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016727, encodeId=ec4b2016e2758, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, objectType=article, longId=165895, objectId=49e916589568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e916589568, replyNumber=0, likeNumber=77, createdTime=2020-01-09, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e916589568, moduleTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e916589568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016736, encodeId=2c812016e36ae, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=怀上二胎却得了晚期肺癌：这个康复故事，临床数据永远不会告诉你, objectType=article, longId=178679, objectId=59951e8679da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59951e8679da, replyNumber=0, likeNumber=81, createdTime=2019-11-30, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59951e8679da, moduleTitle=怀上二胎却得了晚期肺癌：这个康复故事，临床数据永远不会告诉你, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59951e8679da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016738, encodeId=16992016e38e9, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=MGB Biopharma宣布其速效强效抗生素MGB-BP-3治疗艰难梭菌相关性腹泻的IIa期临床数据, objectType=article, longId=181138, objectId=375618113829, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375618113829, replyNumber=0, likeNumber=61, createdTime=2020-05-29, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375618113829, moduleTitle=MGB Biopharma宣布其速效强效抗生素MGB-BP-3治疗艰难梭菌相关性腹泻的IIa期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=375618113829)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016726, encodeId=cbbb2016e26cb, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=2019年欧洲肝脏研究协会（EASL）年会：RNA干扰药物JNJ-3989的临床数据, objectType=article, longId=164220, objectId=392016422049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=392016422049, replyNumber=0, likeNumber=76, createdTime=2020-01-26, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=392016422049, moduleTitle=2019年欧洲肝脏研究协会（EASL）年会：RNA干扰药物JNJ-3989的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=392016422049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016719, encodeId=37312016e19de, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=百济神州公布PARP抑制剂pamiparib的初步临床数据, objectType=article, longId=153822, objectId=ef4b153822c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef4b153822c9, replyNumber=0, likeNumber=174, createdTime=2019-09-18, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef4b153822c9, moduleTitle=百济神州公布PARP抑制剂pamiparib的初步临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef4b153822c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016724, encodeId=e72e2016e24c4, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Glenmark Pharmaceuticals在美国皮肤病学会年会上介绍GBR 830（抗OX40单抗）的2a期临床数据, objectType=article, longId=161549, objectId=c3c3161549aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3c3161549aa, replyNumber=0, likeNumber=73, createdTime=2019-05-10, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3c3161549aa, moduleTitle=Glenmark Pharmaceuticals在美国皮肤病学会年会上介绍GBR 830（抗OX40单抗）的2a期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3c3161549aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016734, encodeId=6ef22016e3410, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=第37届ASRS会议：AU-011治疗原发性脉络膜黑色素瘤的长期临床数据, objectType=article, longId=176177, objectId=d50f1e6177f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50f1e6177f2, replyNumber=0, likeNumber=70, createdTime=2020-05-30, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50f1e6177f2, moduleTitle=第37届ASRS会议：AU-011治疗原发性脉络膜黑色素瘤的长期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d50f1e6177f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016720, encodeId=39a72016e207a, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=内源性代谢调节剂AXA1125作为非酒精性脂肪肝候选药，临床数据证实调节肝脏代谢、炎症和纤维化, objectType=article, longId=158908, objectId=642d15890874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=642d15890874, replyNumber=0, likeNumber=62, createdTime=2019-05-03, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=642d15890874, moduleTitle=内源性代谢调节剂AXA1125作为非酒精性脂肪肝候选药，临床数据证实调节肝脏代谢、炎症和纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=642d15890874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016729, encodeId=619b2016e294d, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=DDW 2019：Rebiotix将发布其基于微生物组修复研究治疗复发性梭状芽孢杆菌艰难梭菌的临床数据, objectType=article, longId=166311, objectId=73e416631194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73e416631194, replyNumber=0, likeNumber=58, createdTime=2019-12-14, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73e416631194, moduleTitle=DDW 2019：Rebiotix将发布其基于微生物组修复研究治疗复发性梭状芽孢杆菌艰难梭菌的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73e416631194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016716, encodeId=79132016e1631, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Nature Digital Medicine：**款针对糖尿病视网膜病变的医疗级AI，临床数据公布, objectType=article, longId=147760, objectId=e67814e760d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e67814e760d7, replyNumber=0, likeNumber=140, createdTime=2019-03-09, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e67814e760d7, moduleTitle=Nature Digital Medicine：**款针对糖尿病视网膜病变的医疗级AI，临床数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e67814e760d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016717, encodeId=451e2016e179f, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=治疗艾滋病，ViiV Healthcare公司的长效注射药物2期临床数据振奋人心, objectType=article, longId=152466, objectId=84471524662d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84471524662d, replyNumber=0, likeNumber=108, createdTime=2019-09-23, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84471524662d, moduleTitle=治疗艾滋病，ViiV Healthcare公司的长效注射药物2期临床数据振奋人心, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84471524662d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016718, encodeId=41a62016e183b, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=百济神州将公布PARP抑制剂Pamiparib的临床数据, objectType=article, longId=152848, objectId=40701528481c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40701528481c, replyNumber=0, likeNumber=90, createdTime=2019-08-14, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40701528481c, moduleTitle=百济神州将公布PARP抑制剂Pamiparib的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40701528481c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016722, encodeId=2a9c2016e2228, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, objectType=article, longId=160662, objectId=4eb716066282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4eb716066282, replyNumber=0, likeNumber=59, createdTime=2019-12-23, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4eb716066282, moduleTitle=辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4eb716066282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016723, encodeId=5aa52016e2335, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Abivax将在两个会议上介绍其先导化合物ABX464的全新临床数据, objectType=article, longId=161014, objectId=2b10161014fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b10161014fa, replyNumber=0, likeNumber=59, createdTime=2019-04-03, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b10161014fa, moduleTitle=Abivax将在两个会议上介绍其先导化合物ABX464的全新临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b10161014fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016721, encodeId=69c62016e2121, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据, objectType=article, longId=160407, objectId=b51a16040ede, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b51a16040ede, replyNumber=0, likeNumber=74, createdTime=2019-08-11, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b51a16040ede, moduleTitle=Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b51a16040ede)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016714, encodeId=792f2016e1493, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组, objectType=article, longId=145963, objectId=4cb0145963c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cb0145963c1, replyNumber=0, likeNumber=57, createdTime=2019-06-30, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cb0145963c1, moduleTitle=II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cb0145963c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016713, encodeId=d5002016e13a1, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=全新一批药物临床数据现场核查名单公示！涉及辉瑞等企业31个注册申请, objectType=article, longId=141493, objectId=cb4d14149355, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb4d14149355, replyNumber=0, likeNumber=57, createdTime=2018-12-21, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb4d14149355, moduleTitle=全新一批药物临床数据现场核查名单公示！涉及辉瑞等企业31个注册申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb4d14149355)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2016712, encodeId=5d682016e120e, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, objectTitle=Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据, objectType=article, longId=139444, objectId=fbd613944467, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbd613944467, replyNumber=0, likeNumber=90, createdTime=2018-08-09, rootId=0, userName=chenlianhui, userId=fa4f352, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbd613944467, moduleTitle=Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbd613944467)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

临床数据

2020-05-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

屡败屡战的千亿级阿尔茨海默病的药企和临床数据解读

2020-01-23

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA

2020-03-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人

2020-01-09

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

怀上二胎却得了晚期肺癌：这个康复故事，临床数据永远不会告诉你

2019-11-30

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

MGB Biopharma宣布其速效强效抗生素MGB-BP-3治疗艰难梭菌相关性腹泻的IIa期临床数据

2020-05-29

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

2019年欧洲肝脏研究协会（EASL）年会：RNA干扰药物JNJ-3989的临床数据

2020-01-26

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

百济神州公布PARP抑制剂pamiparib的初步临床数据

2019-09-18

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Glenmark Pharmaceuticals在美国皮肤病学会年会上介绍GBR 830（抗OX40单抗）的2a期临床数据

2019-05-10

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

第37届ASRS会议：AU-011治疗原发性脉络膜黑色素瘤的长期临床数据

2020-05-30

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

内源性代谢调节剂AXA1125作为非酒精性脂肪肝候选药，临床数据证实调节肝脏代谢、炎症和纤维化

2019-05-03

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

DDW 2019：Rebiotix将发布其基于微生物组修复研究治疗复发性梭状芽孢杆菌艰难梭菌的临床数据

2019-12-14

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Nature Digital Medicine：**款针对糖尿病视网膜病变的医疗级AI，临床数据公布

2019-03-09

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

治疗艾滋病，ViiV Healthcare公司的长效注射药物2期临床数据振奋人心

2019-09-23

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

百济神州将公布PARP抑制剂Pamiparib的临床数据

2019-08-14

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

辉瑞和礼来公司汇报了NGF抑制剂tanezumab在慢性腰痛中的积极III期临床数据

2019-12-23

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Abivax将在两个会议上介绍其先导化合物ABX464的全新临床数据

2019-04-03

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Helsinn和MEI Pharma公布Pracinostat联合阿扎胞苷治疗AML的II期临床数据

2019-08-11

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组

2019-06-30

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

全新一批药物临床数据现场核查名单公示！涉及辉瑞等企业31个注册申请

2018-12-21

chenlianhui (审核中...)

前往app查看评论内容

#临床数据#

Aimmune制药在2018 EAACI上公布AR101治疗花生过敏的全新临床数据

2018-08-09

科室
- - 订阅+
  - 更多科室
工具
服务